Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer

ABSTRACT:

SUBMITTER: Xie Y 

PROVIDER: S-EPMC11228735 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature